Please use this identifier to cite or link to this item:
|Title:||Targeting metals rescues the phenotype in an animal model of tauopathy.|
|Authors:||Sedjahtera, Amelia;Gunawan, Lydia;Bray, Lisa;Hung, Lin Wai;Parsons, Jack;Okamura, Nobuyuki;Villemagne, Victor L;Yanai, Kazuhiko;Liu, Xiang M;Chan, Jacky;Bush, Ashley I;Finkelstein, David I;Barnham, Kevin J;Cherny, Robert A;Adlard, Paul A|
|Affiliation:||The Florey Institute for Neuroscience and Mental Health and The University of Melbourne, Parkville, Victoria, Australia|
Prana Biotechnology, Parkville, Victoria, Australia
Dept of Pharmacology, Tohoku University School of Medicine, Sendai, Japan
Department of Nuclear Medicine, Austin Health, Heidelberg, Victoria, Australia
Department of Pharmacology and Therapeutics, The University of Melbourne, Australia
|Citation:||Metallomics : integrated biometal science 2018; online first: 31 August|
|Abstract:||Tauopathies are characterized by the pathological accumulation of the microtubule associated protein tau within the brain. We demonstrate here that a copper/zinc chaperone (PBT2, Prana Biotechnology) has rapid and profound effects in the rTg(tauP301L)4510 mouse model of tauopathy. This was evidenced by significantly improved cognition, a preservation of neurons, a decrease in tau aggregates and a decrease in other forms of "pathological" tau (including phosphorylated tau and sarkosyl-insoluble tau). Our data demonstrate that one of the primary mechanisms of action of PBT2 in this model may be driven by an interaction on the pathways responsible for the dephosphorylation of tau. Specifically, PBT2 increased protein levels of both the structural and catalytic subunits of protein phosphatase 2A (PP2A), decreased levels of the methyl esterase (PME1) that dampens PP2A activity, and increased levels of the prolyl isomerase (Pin1) that stimulates the dephosphorylation activity of PP2A. None of these effects were observed when the metal binding site of PBT2 was blocked. This highlights the potential utility of targeting metal ions as a novel therapeutic strategy for diseases in which tau pathology is a feature, which includes conditions such as frontotemporal dementia and Alzheimer's disease.|
|Appears in Collections:||Journal articles|
Files in This Item:
There are no files associated with this item.
Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.